| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H24O4 |
| Molecular Weight | 328.4022 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=C(O)C=CC(CC2=C(C)C=C(OCC(O)=O)C=C2C)=C1
InChI
InChIKey=QNAZTOHXCZPOSA-UHFFFAOYSA-N
InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)
Sobetirome (3,5-dimethyl-4[(4'-hydroxy-3'-isopropylbenzyl)-phenoxy] acetic acid, also known as GC-1 and QRX-431, is a member of a class of compounds known as selective thyromimetics. It was firstly developed by Thomas Scanlan’s group at the University of California-San Francisco (UCSF) in 1995. Sobetirome binds selectively to the main hepatic form of thyroid hormone (TH) receptor, TRβ1, compared to TRα1, which is principally responsible for thyrotoxic effects on heart, muscle and bone. Sobetirome also preferentially accumulates in liver. It was originally envisaged that sobetirome could be used to stimulate hepatic pathways that lower cholesterol without harmful side effects and might be used in conjunction with statins. Indeed, sobetirome progressed through preclinical animal studies and Phase I human clinical trials with excellent results and without obvious harmful side effects. Sobetirome had been in phase I clinical trials for the treatment of lipid metabolism disorders and obesity. However, this research has been discontinued.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Single oral doses of 1, 5, 25, 50, 75, 150, 300, and 450 meg of sobetirome have been investigated in a randomized, double-blind, placebo controlled, cross-over, single rising dose safety and tolerance study in healthy male volunteers. All doses were well tolerated with no notable safety concerns. The second phase 1 study involved multiple oral doses of 10, 30, 70 and 100 meg of sobetirome administered daily for 14 days in a randomized, double-blind, placebo controlled, rising multiple-dose safety and tolerance study in healthy male volunteers.
Route of Administration:
Oral
ACTIVE MOIETY
